ZA982907B - Humanized antibodies and methods for forming humanized antibodies - Google Patents

Humanized antibodies and methods for forming humanized antibodies

Info

Publication number
ZA982907B
ZA982907B ZA982907A ZA982907A ZA982907B ZA 982907 B ZA982907 B ZA 982907B ZA 982907 A ZA982907 A ZA 982907A ZA 982907 A ZA982907 A ZA 982907A ZA 982907 B ZA982907 B ZA 982907B
Authority
ZA
South Africa
Prior art keywords
humanized antibodies
methods
forming
vegf
antibodies
Prior art date
Application number
ZA982907A
Other languages
English (en)
Inventor
James A Wells
Manuel Baca
Leanard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25264594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA982907(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA982907B publication Critical patent/ZA982907B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)
  • Semiconductor Lasers (AREA)
ZA982907A 1997-04-07 1998-04-06 Humanized antibodies and methods for forming humanized antibodies ZA982907B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83350497A 1997-04-07 1997-04-07

Publications (1)

Publication Number Publication Date
ZA982907B true ZA982907B (en) 1998-10-09

Family

ID=25264594

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA982908A ZA982908B (en) 1997-04-07 1998-04-06 Anti-VEGF antibodies
ZA982907A ZA982907B (en) 1997-04-07 1998-04-06 Humanized antibodies and methods for forming humanized antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA982908A ZA982908B (en) 1997-04-07 1998-04-06 Anti-VEGF antibodies

Country Status (22)

Country Link
EP (6) EP1695985B1 (xx)
JP (1) JP4191258B2 (xx)
KR (2) KR100794454B1 (xx)
CN (6) CN101210051B (xx)
AT (4) ATE541586T1 (xx)
AU (1) AU740738B2 (xx)
BR (1) BRPI9809388B8 (xx)
CA (1) CA2286397C (xx)
CY (3) CY1111345T1 (xx)
DE (3) DE69841815D1 (xx)
DK (4) DK0971959T3 (xx)
ES (4) ES2349559T3 (xx)
HK (7) HK1025338A1 (xx)
IL (3) IL132239A0 (xx)
LT (1) LTC0973804I2 (xx)
NO (3) NO325823B1 (xx)
NZ (1) NZ500077A (xx)
PT (5) PT2301580E (xx)
SI (5) SI1695985T1 (xx)
TR (1) TR199902818T2 (xx)
WO (1) WO1998045332A2 (xx)
ZA (2) ZA982908B (xx)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
ATE541586T1 (de) * 1997-04-07 2012-02-15 Genentech Inc Behälter mit anti-vegf antikörpern
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
PT1135498E (pt) 1998-11-18 2008-04-30 Genentech Inc Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
NZ514918A (en) 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
WO2001081401A1 (fr) 2000-04-21 2001-11-01 Fuso Pharmaceutical Industries, Ltd. Nouvelles collectines
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BR0307548A (pt) * 2002-02-11 2006-01-17 Genentech Inc Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
CA2487321A1 (en) 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1629010A1 (en) 2003-05-30 2006-03-01 Genentech, Inc. Treatment with anti-vegf antibodies
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
EP2275534A1 (fr) 2003-12-02 2011-01-19 Institut Pasteur Nouvelle souche de coronavirus associé au SRAS et ses applications
EP1716181B1 (en) 2004-02-19 2009-12-16 Genentech, Inc. Cdr-repaired antibodies
MX2007000784A (es) 2004-07-20 2007-04-09 Genentech Inc Inhibidores de proteina 4 tipo angiopoietina, combinaciones y su uso.
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
SI1802334T1 (sl) 2004-10-21 2012-12-31 Genentech, Inc. Postopek za zdravljenje intraokularnih neovaskularnih bolezni
UA96139C2 (xx) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)$антитело к нейропилину-1 (nrp1)
CN103360496B (zh) 2006-01-05 2015-11-18 健泰科生物技术公司 抗ephb4抗体及其使用方法
BRPI0706935A2 (pt) 2006-01-20 2011-04-19 Genentech Inc anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CA2652733C (en) * 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2032604A2 (en) 2006-06-06 2009-03-11 Genentech, Inc. Anti-dll4 antibodies and methods using same
CN1903880B (zh) * 2006-08-02 2010-05-12 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子vegf-e抗原及其编码基因与应用
PL2056874T3 (pl) 2006-08-21 2013-02-28 Hoffmann La Roche Leczenie nowotworu przeciwciałem przeciw VEGF
CN101148474B (zh) * 2006-09-21 2014-06-11 上海杰隆生物工程股份有限公司 人源人血管内皮生长因子单克隆抗体及其制备方法
KR20140148491A (ko) 2006-12-19 2014-12-31 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제
CN101754771B (zh) 2007-05-17 2015-03-04 健泰科生物技术公司 抗神经毡蛋白2抗体对肿瘤转移的抑制
KR101523788B1 (ko) 2007-05-17 2015-06-26 제넨테크, 인크. 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
MX344733B (es) 2007-11-09 2017-01-04 Genentech Inc * Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina.
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
MX347972B (es) * 2008-06-25 2017-05-22 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el vegf.
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
MX2011004001A (es) 2008-10-14 2011-05-19 Genentech Inc Variantes de inmunoglobulinas y sus usos.
CN102272148A (zh) 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
AU2009316409A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
WO2010075420A1 (en) 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010111746A1 (en) * 2009-04-03 2010-10-07 Vegenics Limited Anti-vegf-d antibodies
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
CA2838400A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2534355T3 (es) 2009-06-17 2015-04-21 Abbvie Biotherapeutics Inc. Anticuerpos anti-VEGF y sus usos
WO2011008696A2 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
EP2459591B1 (en) 2009-07-31 2014-08-20 Genentech, Inc. Inhibition of tumor metastasis using anti-g-csf-antibodies
WO2011022264A1 (en) 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
US20110064670A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011033006A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
CN102051396B (zh) * 2009-11-04 2014-07-16 无锡天演生物技术有限公司 雁阵式定域随机突变方法及其在单抗分子进化技术中的应用
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
SG2014011340A (en) 2009-12-21 2014-07-30 Genentech Inc Antibody formulation
MX2012007379A (es) 2009-12-23 2012-08-31 Genentech Inc Anticuerpos anti-bv8 y usos de los mismos.
FR2955773B1 (fr) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
KR101839161B1 (ko) 2010-02-23 2018-03-16 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
CN102863533B (zh) * 2010-06-21 2013-12-11 中国科学技术大学 抗体人源化改造方法
JP2013539962A (ja) 2010-07-09 2013-10-31 ジェネンテック， インコーポレイテッド 抗ニューロピリン抗体及び使用方法
CN104569395A (zh) 2010-07-19 2015-04-29 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
EP2866032A1 (en) 2010-07-19 2015-04-29 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Ｆｇｆｒ１ 세포밖 도메인 조합치료
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
ES2899186T3 (es) * 2010-12-31 2022-03-10 Bioatla Inc Humanización rápida de anticuerpos
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
CN103476795B (zh) 2011-03-29 2016-07-06 罗切格利卡特公司 抗体Fc变体
CN111643504A (zh) 2011-04-01 2020-09-11 基因泰克公司 Akt抑制剂化合物和化疗剂的组合以及使用方法
WO2012145539A1 (en) 2011-04-20 2012-10-26 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
CA2842481A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
EP2825558B1 (en) 2012-03-13 2019-05-15 F.Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
MY186099A (en) 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
IN2014DN11157A (xx) 2012-07-13 2015-10-02 Roche Glycart Ag
KR20150038593A (ko) 2012-08-07 2015-04-08 제넨테크, 인크. 교모세포종의 치료를 위한 조합 요법
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
FR2998579B1 (fr) 2012-11-27 2015-06-19 Commissariat Energie Atomique Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CA2906057A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Antibody formulations
CA2904969A1 (en) * 2013-03-13 2014-10-09 Imaginab, Inc. Antigen binding constructs to cd8
JP2016524611A (ja) 2013-05-23 2016-08-18 ファイヴ プライム セラピューティクス インク がんを治療する方法
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
EA202090707A1 (ru) 2013-10-25 2020-12-30 Акселерон Фарма, Инк. Эндоглиновые пептиды для лечения фиброзных заболеваний
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EA035037B1 (ru) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
PT3083680T (pt) 2013-12-20 2020-03-17 Hoffmann La Roche Anticorpos humanizados anti-tau(ps422) e métodos de utilização
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
CN106132439A (zh) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
CA2947456C (en) 2014-05-12 2023-03-14 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
DK3180018T3 (da) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
BR112017009728A2 (pt) 2014-11-10 2018-02-06 Genentech, Inc. anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
SG11201704707PA (en) 2014-12-23 2017-07-28 Genentech Inc Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
CN107810196B (zh) * 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
RU2765242C2 (ru) 2015-08-07 2022-01-27 Имаджинаб, Инк. Антигенсвязывающие конструкции против молекул-мишеней
BR112018007703A2 (pt) 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
TWI772275B (zh) 2015-11-03 2022-08-01 美商健生生物科技公司 特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
WO2017079419A1 (en) 2015-11-05 2017-05-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
JP7430485B2 (ja) 2015-11-18 2024-02-13 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド 眼科用製剤のための薬剤パッケージ
KR102354198B1 (ko) 2015-11-18 2022-01-20 에스아이오2 메디컬 프로덕츠, 인크. Vegf-길항제의 액체 제제를 포함하는 사전-충전된 제약 패키지
JP2019501687A (ja) 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
CA3011638C (en) 2016-01-26 2023-01-10 Formycon Ag Liquid formulation of a vegf antagonist
CN105481981B (zh) * 2016-01-27 2019-03-19 中国人民解放军第二军医大学 靶向vegf双特异性抗体及其用途
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
MX2018012492A (es) 2016-04-15 2019-06-06 Genentech Inc Métodos para monitorear y tratar el cáncer.
WO2018009811A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
CN109890982B (zh) 2016-07-08 2023-07-07 基因泰克公司 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
EP3496752B1 (en) 2016-08-12 2022-05-18 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
EP3504236B1 (en) * 2016-08-23 2020-09-23 Medimmune Limited Anti-vegf-a antibodies and uses thereof
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
KR20190134631A (ko) 2017-03-01 2019-12-04 제넨테크, 인크. 암의 진단 및 치료 방법
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CN111479588A (zh) 2017-12-29 2020-07-31 豪夫迈·罗氏有限公司 用于改善抗vegf抗体的vegf受体阻断选择性的方法
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
TW201943428A (zh) 2018-04-16 2019-11-16 大陸商上海岸闊醫藥科技有限公司 預防或治療腫瘤療法副作用的方法
KR20210015902A (ko) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 Psma 결합제 및 이의 용도
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
US20220185875A1 (en) 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
KR20220004744A (ko) 2019-05-03 2022-01-11 제넨테크, 인크. 항-pd-l1 항체를 이용하여 암을 치료하는 방법
CN113795514A (zh) * 2019-05-09 2021-12-14 豪夫迈·罗氏有限公司 制备抗体的方法
AU2019461286B2 (en) 2019-08-09 2024-01-04 Anhui Biox Vision Biological Technology Co., Ltd. Anti-VEGF-anti-PD1 bispecific antibody with new-type structure
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115605507A (zh) 2020-03-13 2023-01-13 基因泰克公司（Us） 抗白介素-33抗体及其用途
CN113461824A (zh) 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 一种构建多特异性抗体的平台
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
FR3110838B1 (fr) 2020-05-28 2022-06-24 Commissariat Energie Atomique Complexe immunomodulateur et ses applications pour la thérapie
JP2023531537A (ja) 2020-06-30 2023-07-24 メンドゥス・ベスローテン・フェンノートシャップ 卵巣癌ワクチンでの白血病由来細胞の使用
CN114106190A (zh) 2020-08-31 2022-03-01 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
EP4243828A1 (en) 2020-11-13 2023-09-20 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
MX2023008909A (es) 2021-01-28 2023-10-23 Janssen Biotech Inc Proteínas de unión a psma y usos de estas.
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
EP4363449A2 (en) 2021-07-02 2024-05-08 Genentech, Inc. Methods and compositions for treating cancer
CN117715936A (zh) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 用于治疗癌症的方法和组合物
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2001774C (en) * 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69233367T2 (de) * 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DK0666868T4 (da) * 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
AU696764B2 (en) * 1994-03-08 1998-09-17 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE541586T1 (de) * 1997-04-07 2012-02-15 Genentech Inc Behälter mit anti-vegf antikörpern

Also Published As

Publication number Publication date
LTPA2007004I1 (lt) 2019-12-27
HK1114621A1 (en) 2008-11-07
CN1191276C (zh) 2005-03-02
DE69842174D1 (de) 2011-04-21
NO2017039I2 (no) 2018-08-28
CN101838328A (zh) 2010-09-22
SI2301580T1 (sl) 2012-05-31
PT1787999E (pt) 2010-11-11
EP2301580B1 (en) 2012-01-18
JP2001502922A (ja) 2001-03-06
NO2017039I1 (no) 2017-08-01
DK0971959T3 (da) 2006-05-15
DK1787999T3 (da) 2010-11-15
WO1998045332A3 (en) 1998-12-03
IL175906A (en) 2010-05-31
ATE501170T1 (de) 2011-03-15
SI0973804T1 (sl) 2007-06-30
PT971959E (pt) 2006-05-31
CN101210051A (zh) 2008-07-02
AU740738B2 (en) 2001-11-15
BR9809388B1 (pt) 2013-06-04
KR100794454B1 (ko) 2008-01-16
EP1695985A3 (en) 2006-11-22
EP0971959A1 (en) 2000-01-19
HK1025338A1 (en) 2000-11-10
EP2338915A3 (en) 2011-10-12
DE69832970T2 (de) 2006-08-10
HK1149501A1 (en) 2011-10-07
BRPI9809388B8 (pt) 2021-05-25
CA2286397C (en) 2011-02-15
HK1139425A1 (en) 2010-09-17
JP4191258B2 (ja) 2008-12-03
CY1111520T1 (el) 2015-08-05
PT1695985E (pt) 2011-06-06
ES2349559T3 (es) 2011-01-05
SI1787999T1 (sl) 2010-12-31
CY1112757T1 (el) 2016-02-10
CN101210050B (zh) 2010-12-08
NO2019045I1 (no) 2019-12-11
SI0971959T1 (sl) 2006-06-30
TR199902818T2 (xx) 2000-05-22
AU7102398A (en) 1998-10-30
CN101210051B (zh) 2012-12-26
KR20010006115A (ko) 2001-01-26
EP2338915A2 (en) 2011-06-29
HK1204329A1 (en) 2015-11-13
WO1998045332A2 (en) 1998-10-15
HK1095334A1 (en) 2007-05-04
EP3260468A1 (en) 2017-12-27
HK1114622A1 (en) 2008-11-07
EP2301580A1 (en) 2011-03-30
ES2256935T3 (es) 2006-07-16
ATE314395T1 (de) 2006-01-15
DE69832970D1 (de) 2006-02-02
DK1695985T3 (da) 2011-06-14
DK2301580T3 (da) 2012-05-14
CN101210050A (zh) 2008-07-02
ZA982908B (en) 1999-01-21
KR100856995B1 (ko) 2008-09-04
EP2301580A9 (en) 2011-09-14
EP2336190A2 (en) 2011-06-22
ES2361267T3 (es) 2011-06-15
IL132239A0 (en) 2001-03-19
SI1695985T1 (sl) 2011-06-30
CY1111345T1 (el) 2015-08-05
CN1259961A (zh) 2000-07-12
NZ500077A (en) 2001-10-26
CN101665536A (zh) 2010-03-10
NO994870L (no) 1999-12-06
NO994870D0 (no) 1999-10-06
ATE476664T1 (de) 2010-08-15
PT973804E (pt) 2007-03-30
ES2380575T3 (es) 2012-05-16
KR20010006116A (ko) 2001-01-26
BR9809388A (pt) 2000-06-13
IL175906A0 (en) 2006-10-05
IL132240A (en) 2006-09-05
NO325823B1 (no) 2008-07-21
EP1695985B1 (en) 2011-03-09
PT2301580E (pt) 2012-05-02
CN104231078A (zh) 2014-12-24
CA2286397A1 (en) 1998-10-15
ATE541586T1 (de) 2012-02-15
EP1695985A2 (en) 2006-08-30
EP2336190A3 (en) 2011-10-05
DE69841815D1 (de) 2010-09-16
CN101665536B (zh) 2013-07-03
EP0971959B1 (en) 2005-12-28
LTC0973804I2 (lt) 2020-04-27

Similar Documents

Publication Publication Date Title
NO2019045I1 (no) Ranibizumab - Forlenget SPC
SI1325932T1 (xx)